Mobile Magnetic Nanocatalysts for Bioorthogonal Targeted Cancer Therapy. (15th January 2018)

• Record Type: Journal Article
• Authors: Hoop, Marcus; Ribeiro, Ana Sofia; Rösch, Daniel; Weinand, Philipp; Mendes, Nuno; Mushtaq, Fajer; Chen, Xiang‐Zhong; Shen, Yang; Pujante, Carlos Franco; Puigmartí‐Luis, Josep; Paredes, Joana; Nelson, Bradley J.; Pêgo, Ana Paula; Pané, Salvador
• Is Part Of: Advanced functional materials. Volume 28:Number 25(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-01-15
• Subjects: bioorthogonal chemistry -- cancer therapy -- iron–palladium -- magnetic actuation -- nanowires; Materials -- Periodicals; Chemical vapor deposition -- Periodicals; 620.11
• DOI: 10.1002/adfm.201705920
• Languages: English
• ISSNs: 1616-301X

Abstract

Abstract: The use of magnetic nanorobots to activate chemotherapeutic prodrugs represents a promising alternative to current chemotherapeutic treatments. Here, a hybrid nanowire (NW) for targeted bioorthogonally driven activation of the latent chemotherapeutic prodrug 5‐fluoro‐1‐propargyl‐uracil (Pro‐5‐FU) in in vitro and in vivo cancer models is proposed. The NWs are composed of magnetic iron (Fe) and palladium (Pd), a known bioorthogonal catalyst. In vitro tests with a cancer cell line showed no significant cytotoxic effect by the NWs. In contrast, NWs combined with Pro‐5‐FU lead to a significant reduction of cell viability, similarly to the one induced by its active chemotherapeutic counterpart 5‐fluorouracil (5‐FU). The reduction in cell viability is attributed to the catalytic activation of Pro‐5‐FU into 5‐FU. To demonstrate their targeted therapeutic abilities, magnetic fields are used to attract the FePd NWs to a predefined area within a cultured cancer cell population, causing a local Pro‐5‐FU activation, and subsequent cell death in this region. As a proof of concept, NWs are injected in cancer tumor xenografts. The intraperitoneal injection of Pro‐5‐FU significantly retards tumour growth without causing significant side effects. This work presents a novel chemotherapeutic approach combining nanorobotics and bioorthogonal activation of prodrugs as an efficient alternative to conventional chemotherapy. Abstract : Iron–palladium‐based magnetic nanocatalysts are used for bioorthogonally driven targeted cancer therapy. The alloy nanocatalysts exhibit bioorthogonal activity by turning a latent prodrug to an anticancer agent. The therapeutic efficiency is demonstrated both in vitro and in vivo. This study presents a novel cancer therapy approach combining nanotechnology, nanorobotics, and bioorthogonal chemistry as an efficient alternative to conventional chemotherapy approaches.